Advil Ibuprofen Tablets Recalled for Illegible Labels
Glaxosmithkline Consumer Healthcare is recalling Advil ibuprofen 200 mg tablets because adhesive migrated onto labels, causing them to tear when peeled. This affects 321,246 tablets distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I classification requires a minimum severity score of 4. Although no illnesses or injuries have been reported, the labeling defect affecting an over-the-counter medication is considered a serious potential hazard by the FDA, as illegible labels could impede proper use of the medication.
Plain-English summary
Glaxosmithkline Consumer Healthcare is recalling Advil ibuprofen 200 mg tablets due to a labeling defect. The affected products include 360-count bottles (UPC 3 0573 0154 60 4) and 200-count bottles (UPC 3 0573 0154 21 5).
The recall is due to adhesive migration onto a portion of the label, causing the label to tear when peeled back. This results in illegible labeling that could prevent consumers from properly reading dosage, warning, and safety information on the medication.
Approximately 321,246 tablets have been distributed nationwide. The affected lot codes are EJ2218, EJ2219, and EJ2220 (expiring 09/2023), and Lot 953D (expiring 05/2025).
No illnesses or injuries have been reported. Consumers with affected products should stop use and contact their pharmacy or healthcare provider for guidance.
The recalled product
- Product
- Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940
- Manufacturer
- Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
- Hazard
- illegible-label
- labeling-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- a) Lots EJ2218
- EJ2219
- EJ2220
- Exp 09/2023
- b) Lot 953D
- Exp 05/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27